Advertisement
U.S. markets open in 3 hours 20 minutes
Advertisement

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
55.42+0.60 (+1.09%)
At close: 04:00PM EST
55.21 -0.21 (-0.38%)
After hours: 05:48PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close54.82
Open54.71
Bid0.00 x 800
Ask0.00 x 800
Day's Range54.25 - 55.64
52 Week Range50.27 - 86.29
Volume1,289,116
Avg. Volume1,775,654
Market Cap12.42B
Beta (5Y Monthly)0.70
PE Ratio (TTM)29.48
EPS (TTM)1.88
Earnings DateFeb 05, 2024 - Feb 09, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est74.78
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
41% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for INCY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Incyte Corporation
    Analyst Report: Incyte CorporationIncyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more